CANVAS: No Difference in Canagliflozin Effects by Prior CV Status CANVAS: No Difference in Canagliflozin Effects by Prior CV Status
A new analysis of CANVAS finds that canagliflozin reduces CV and renal risks whether the type 2 diabetes patients had prior CVD or not, although a discussant queries benefit in primary prevention.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
More News: Canagliflozin | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Invokana